The kick-off meeting of the AD-RIDDLE (“Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement”) project took place in Stockholm on 3 and 4 June 2024. Recent advances in the areas of multi-domain lifestyle interventions and pharmacological treatments call for a transformation of Alzheimer’s disease clinical pathway. AD-RIDDLE sets out to improve this pathway by means of developing a modular toolbox, offering instruments for risk-reduction, early detection, diagnosis and intervention. Specifically, digital cognitive assessment tools, blood-based biomarkers and lifestyle-based intervention protocols shall be optimised and streamlined into one digital portal, to optimise the clinical pathway of Alzheimer’s disease.
During the kick-off meeting in Stockholm, representatives of 24 partners from academia, healthcare, industry and non-profit organisations met to discuss different work packages, facilitate partnerships and set the stage for effective collaboration throughout the five-year project. Within the consortium, Alzheimer Europe leads two work packages concerning facilitation of the real-world implementation of AD-RIDDLE (e.g., ethical, policy, health economic considerations) as well as communication and public involvement. Angela Bradshaw (Director for Research), Ana Diaz (Public Involvement Lead), Sarah Campill (Public Involvement Officer) and Lukas Duffner (Project Officer) joined the kick-off meeting on behalf of Alzheimer Europe. The AD-RIDDLE project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU), under grant agreement No 101132933 (2024-2029). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe, with Davos Alzheimer’s Collaborative, Combinostics OY., Cambridge Cognition Ltd., C2N Diagnostics LLC, and neotiv GmbH.
